Co-diagnostics, INC 8-K filings

Co-Diagnostics, Inc. (CODX) received a notice from Nasdaq on January 10, 2025, indicating that its common stock price has fallen below the minimum $1.00 per share required for continued listing.

Co-Diagnostics Inc. has amended its previous 8-K filing to disclose that it will conduct annual Say-on-Pay votes following a shareholder vote at its 2024 Annual Meeting.

Co-Diagnostics reported a revenue decline in Q3 2024, primarily due to the timing of grant revenue recognition, alongside an increased net loss compared to the previous year.

Co-Diagnostics, Inc. held its 2024 annual meeting, electing a director, approving executive compensation, and ratifying the appointment of its accounting firm.

Co-Diagnostics saw a significant increase in revenue and reduced operating losses in Q2 2024, driven by grant milestones and lower expenses, while also submitting a key FDA application.

Co-Diagnostics has submitted its first FDA 510(k) application for its Co-Dx PCR Pro platform and COVID-19 test for over-the-counter use.

Co-Diagnostics reported a decrease in revenue and an increased net loss for the first quarter of 2024, alongside strategic expansions and leadership changes.

Co-Diagnostics, Inc. has appointed Richard Abbott as President, effective March 15, 2024.

Co-Diagnostics reported a significant decrease in revenue for 2023 due to reduced demand for COVID-19 tests, alongside increased investment in new platform development.